A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTITUMOR ACTIVITY OF PF-07260437 IN ADVANCED OR METASTATIC SOLID TUMORS

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 05 Jan 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs PF-07260437 (Primary)
Indications Advanced breast cancer; Endometrial cancer; Ovarian cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions
Sponsors Pfizer

07 Nov 2023 Status changed from active, no longer recruiting to discontinued.
15 Sep 2023 Planned End Date changed from 25 Sep 2025 to 15 Jan 2024.
15 Sep 2023 Planned primary completion date changed from 25 Sep 2025 to 15 Jan 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com